scholarly journals Relapse of hairy cell leukemia after 2-chlorodeoxyadenosine: long-term follow-up of the Northwestern University experience

Blood ◽  
1996 ◽  
Vol 88 (6) ◽  
pp. 1954-1959 ◽  
Author(s):  
MS Tallman ◽  
D Hakimian ◽  
AW Rademaker ◽  
C Zanzig ◽  
E Wollins ◽  
...  
Keyword(s):  
Relapse Rate ◽  
Hairy Cell Leukemia ◽  
Progression Free Survival ◽  
Hairy Cell ◽  
Cell Leukemia ◽  
Term Outcome ◽  
Long Term Outcome ◽  
Prior Therapy ◽  
Long Term Follow Up

Although 2-chlorodeoxyadenosine (2-CdA) is effective in inducing complete remissions (CRs) in the majority of patients with hairy cell leukemia (HCL), neither the actual relapse rate, the clinical factors that may predict relapse, the long-term outcome, nor the response rate to re-treatment at relapse has been clearly determined. Fifty-two consecutive patients with previously untreated or treated HCL were treated with 2-CdA at a dose of 0.1 mg/kg/d by continuous intravenous infusion for 7 days. Of 50 assessable patients, 40 (80%) achieved CR, and 9 (18%) achieved partial remission (PR). A total of 7 patients (14%) have relapsed, at a median duration of 24 months (range, 12 to 44). Of the 7 relapsed patients, 5 were re-treated with a second cycle of 2-CdA; 2 achieved a second CR and 3 attained a PR. The progression- free survival (PFS) rate is 72% at 4 years for all 52 patients and 83% for patients achieving CR. The overall survival (OS) rate is 86% at 4 years. Only prior therapy was predictive of relapse. The majority of patients achieve durable CRs with a single cycle of 2-CdA. The relapse rate is low and the long-term prognosis is excellent. The few patients who relapse can attain second remissions after re-treatment with 2-CdA.

Long Term Follow-Up of Patients with Hairy Cell Leukemia (HCL).

Blood ◽  
2004 ◽  
Vol 104 (11) ◽  
pp. 3473-3473 ◽  
Author(s):  
Farhad Ravandi-Kashani ◽  
Hagop Kantarjian ◽  
Stefan Faderl ◽  
Susan O’Brien ◽  
Deborah Thomas ◽  
...  
Keyword(s):  
Hairy Cell Leukemia ◽  
Nucleoside Analogs ◽  
Time Of Death ◽  
Hairy Cell ◽  
Cell Leukemia ◽  
Term Outcome ◽  
Long Term Outcome ◽  
Long Term Follow Up

Interferon-a (IFN-a) and, more recently, nucleoside analogs (NA) such as 2-CDA and pentostatin have been used with significant success to treat HCL. A single course of 2-CDA produces response rates over 75%, with responses maintained for 4 years in 75% of pts. Similar results have been observed with pentostatin. (Dearden et al, Br J Haematol1999;106:515). To learn more about long-term outcome, we reviewed 234 pts with untreated HCL seen at the MDACC over a 30-year period; their median follow-up was 122 months from diagnosis (up to 387 months). Their median age at diagnosis was 50 years (range 23–83 years). Survival was superior among the 173 pts given either 2-CDA (n = 161) or pentostatin (n = 12) compared to those never given either NA (p = 0.042). Figure Figure Relapse occurred in 32 of 176 pts who received 2-CDA as their first chemotherapy either at MDACC or before presenting to MDACC. Therapy for relapse after 2-CDA included rituximab (N=9), a second course of 2-CDA (n=9), a second course of 2-CDA followed by rituximab (n=8), and other (n=6). No statistically significant differences in survival were seen possibly due to small pt numbers. The estimated 10-year and 20-year survival (from diagnosis) for the 176 pts who received 2-CDA as first chemotherapy was 84%, and 65%, respectively. Figure Figure The majority of pts who died were not in remission at time of death and thus presumably died of HCL. Hence alternatives to NA are needed in at least some pts, and we are evaluating whether covariates exist that might distinguish pts who do and do not relapse and, among the former, pts whose remissions are short. Pending identification of the latter and keeping in mind the length of the average remission, alternatives to NA should have very little toxicity. We have begun to add rituximab to 2-CDA to lengthen remission duration and thus extend survival in pts with untreated HCL.

scholarly journals Long term outcome of patients with hairy cell leukemia treated with pentostatin

Cancer ◽  
1999 ◽  
Vol 85 (1) ◽  
pp. 65-71 ◽  
Author(s):  
Patricia Ribeiro ◽  
Fadhela Bouaffia ◽  
Pierre-Yves Peaud ◽  
Michel Blanc ◽  
Bruno Salles ◽  
...  
Keyword(s):  
Hairy Cell Leukemia ◽  
Hairy Cell ◽  
Cell Leukemia ◽  
Term Outcome ◽  
Long Term Outcome

Clinical characteristics and long-term outcome of young hairy cell leukemia patients treated with cladribine: a single-institution series

Blood ◽  
2014 ◽  
Vol 123 (2) ◽  
pp. 177-183 ◽  
Author(s):  
Joshua D. Rosenberg ◽  
Carol Burian ◽  
Jill Waalen ◽  
Alan Saven
Keyword(s):  
Hairy Cell Leukemia ◽  
Second Primary ◽  
Hairy Cell ◽  
Cell Leukemia ◽  
Term Outcome ◽  
Long Term Outcome ◽  
Increased Risk ◽  
Key Points ◽  
Second Primary Malignancies

Key Points HCL patients ≤40 years at diagnosis treated with cladribine obtain complete and durable responses, but ultimately relapse. There was no increased risk of second primary malignancies in young hairy cell leukemia patients followed for protracted periods.

Treatment of hairy cell leukemia with 2-chlorodeoxyadenosine (2-CdA): long-term follow-up of the Northwestern University experience

Blood ◽  
2005 ◽  
Vol 106 (1) ◽  
pp. 241-246 ◽  
Author(s):  
Punit Chadha ◽  
Alfred W. Rademaker ◽  
Prateek Mendiratta ◽  
Benjamin Kim ◽  
Darren M. Evanchuk ◽  
...  
Keyword(s):  
Hairy Cell Leukemia ◽  
Progression Free Survival ◽  
Hairy Cell ◽  
Cell Leukemia ◽  
Long Term Outcomes ◽  
Northwestern University ◽  
Long Term Follow Up ◽  
University Experience

2-chlorodeoxyadenosine (2-CdA), a purine analog, has become universally accepted as the agent of choice in treating hairy cell leukemia (HCL). However, few studies have reported long-term outcomes after 2-CdA treatment. Between January 1990 and June 2003, 86 consecutive patients with HCL were treated with a single 7-day course of 2-CdA by continuous infusion at a dose of 0.1 mg/kg per day. Of the 86 patients (mean age: 49 years), 67 patients (79%) achieved a complete remission (CR); 18 patients (21%) achieved a partial remission (PR); and 1 patient's response was unable to be assessed. The progression-free survival (PFS) for initial relapse after 12 years was 54%. At a median follow-up of 9.7 years (range, 0.3-13.8 years), 31 (36%) of 85 patients relapsed. There were 23 relapsed patients treated with a second cycle of 2-CdA; 2 patients were treated with alternative agents; and 6 patients were observed. Of the 23 relapsed patients retreated with 2-CdA, 12 (52%) achieved a CR and 7 (30%) patients achieved a PR (overall response rate: 83%). The overall survival (OS) rate after 12 years was 87%. There were 15 patients (17%) who developed other malignancies. Long-term follow-up of up to 14 years (median: 9.7 years) showed an excellent PFS and OS for HCL patients after 2-CdA treatment.

scholarly journals Long-term outcome with pentostatin treatment in hairy cell leukemia patients. A French retrospective study of 238 patients

Leukemia ◽  
2003 ◽  
Vol 17 (1) ◽  
pp. 45-51 ◽  
Author(s):  
F Maloisel ◽  
L Benboubker ◽  
M Gardembas ◽  
B Coiffier ◽  
M Divine ◽  
...  
Keyword(s):  
Retrospective Study ◽  
Hairy Cell Leukemia ◽  
Hairy Cell ◽  
Cell Leukemia ◽  
Term Outcome ◽  
Long Term Outcome

Long-term outcome of hairy cell leukemia treated with 2-chlorodeoxyadenosine

1999 ◽  
Vol 78 (3) ◽  
pp. 139-144 ◽  
Author(s):  
U. Jehn ◽  
R. Bartl ◽  
H. Dietzfelbinger ◽  
U. Vehling-Kaiser ◽  
B. Wolf-Hornung ◽  
...  
Keyword(s):  
Hairy Cell Leukemia ◽  
Hairy Cell ◽  
Cell Leukemia ◽  
Term Outcome ◽  
Long Term Outcome

scholarly journals Long term follow-up of a phase II study of cladribine with concurrent rituximab with hairy cell leukemia variant

2021 ◽  
Author(s):  
Dai Chihara ◽  
Evgeny Arons ◽  
Maryalice Stetler-Stevenson ◽  
Constance M Yuan ◽  
Hao-Wei Wang ◽  
...  
Keyword(s):  
Phase Ii ◽  
Hairy Cell Leukemia ◽  
Residual Disease ◽  
Phase Ii Study ◽  
Progression Free Survival ◽  
Hairy Cell ◽  
Cell Leukemia ◽  
Long Term Follow Up

Hairy cell leukemia variant (HCLv) responds poorly to purine analog monotherapy. Rituximab concurrent with cladribine (CDAR) improves response rate, but long-term outcomes are unknown. We report final results of a phase II study of CDAR for patients with HCLv. Twenty patients with 0-1 prior courses of cladribine and/or rituximab, including 8 previously untreated, received cladribine 0.15 mg/kg days 1-5 with 8 weekly rituximab doses 375 mg/m2. Patients received a 2nd rituximab course ≥6 months after cladribine, if/when minimal residual disease (MRD) was detected in blood. The complete remission (CR) rate from CDAR was 95%, 95% confidence interval (95%CI) 75-100%. Sixteen of 20 patients (80%, 95% CI: 56-94%) became MRD-negative by bone marrow at 6 months. The median duration of MRD-negative CR was 70.1 months and 7 of 16 are still MRD-negative up to 120 months. With median follow-up of 69.7 months, 11 patients received delayed rituximab and the 5-year progression-free survival (PFS) and overall survival (OS) were 63.3% and 73.9%, respectively. Five patients with TP53 mutations had shorter PFS (median: 36.4 months vs unreached, p=0.0024) and OS (median: 52.4 months vs unreached, p=0.032). MRD-negative CR at 6 months was significantly associated with longer PFS (unreached vs 17.4 months, p<0.0001) and OS (unreached vs 38.2 months, p<0.0001). Lack of MRD in blood at 6 months was also predictive of longer PFS and OS (p<0.0001). After progression following CDAR, median OS was 29.7 months. CDAR is effective in HCLv with better outcome in patients who achieved MRD-negative CR.

scholarly journals Moxetumomab pasudotox in heavily pre-treated patients with relapsed/refractory hairy cell leukemia (HCL): long-term follow-up from the pivotal trial

2021 ◽  
Vol 14 (1) ◽  
Author(s):  
Robert J. Kreitman ◽  
◽  
Claire Dearden ◽  
Pier Luigi Zinzani ◽  
Julio Delgado ◽  
...  
Keyword(s):  
Hairy Cell Leukemia ◽  
Residual Disease ◽  
Braf Inhibitor ◽  
Nucleoside Analogs ◽  
High Rate ◽  
Hairy Cell ◽  
Cell Leukemia ◽  
Long Term Follow Up

Abstract Background Moxetumomab pasudotox is a recombinant CD22-targeting immunotoxin. Here, we present the long-term follow-up analysis of the pivotal, multicenter, open-label trial (NCT01829711) of moxetumomab pasudotox in patients with relapsed/refractory (R/R) hairy cell leukemia (HCL). Methods Eligible patients had received ≥ 2 prior systemic therapies, including ≥ 2 purine nucleoside analogs (PNAs), or ≥ 1 PNA followed by rituximab or a BRAF inhibitor. Patients received 40 µg/kg moxetumomab pasudotox intravenously on Days 1, 3, and 5 of each 28-day cycle for up to six cycles. Disease response and minimal residual disease (MRD) status were determined by blinded independent central review. The primary endpoint was durable complete response (CR), defined as achieving CR with hematologic remission (HR, blood counts for CR) lasting > 180 days. Results Eighty adult patients were treated with moxetumomab pasudotox and 63% completed six cycles. Patients had received a median of three lines of prior systemic therapy; 49% were PNA-refractory, and 38% were unfit for PNA retreatment. At a median follow-up of 24.6 months, the durable CR rate (CR with HR > 180 days) was 36% (29 patients; 95% confidence interval: 26–48%); CR with HR ≥ 360 days was 33%, and overall CR was 41%. Twenty-seven complete responders (82%) were MRD-negative (34% of all patients). CR lasting ≥ 60 months was 61%, and the median progression-free survival without the loss of HR was 71.7 months. Hemolytic uremic and capillary leak syndromes were each reported in ≤ 10% of patients, and ≤ 5% had grade 3–4 events; these events were generally reversible. No treatment-related deaths were reported. Conclusions Moxetumomab pasudotox resulted in a high rate of durable responses and MRD negativity in heavily pre-treated patients with HCL, with a manageable safety profile. Thus, it represents a new and viable treatment option for patients with R/R HCL, who currently lack adequate therapy. Trial registration ClinicalTrials.gov identifier: NCT01829711; first submitted: April 9, 2013. https://clinicaltrials.gov/ct2/show/NCT01829711

scholarly journals Incidence of response and long-term follow-up in patients with hairy cell leukemia treated with recombinant interferon alfa-2a [see comments]

Blood ◽  
1990 ◽  
Vol 75 (4) ◽  
pp. 839-845 ◽  
Author(s):  
E Berman ◽  
G Heller ◽  
S Kempin ◽  
T Gee ◽  
LL Tran ◽  
...  
Keyword(s):  
Disease Progression ◽  
Hairy Cell Leukemia ◽  
Interferon Alfa ◽  
Hairy Cell ◽  
Cell Leukemia ◽  
Minor Response ◽  
Recombinant Interferon ◽  
Long Term Follow Up

Abstract Thirty-five evaluable patients with hairy cell leukemia (HCL) were treated with recombinant interferon alfa-2a (rIFN-alpha 2a), given at a dose of 3 X 10(6) units (U) intramuscularly (IM) daily for 6 months followed by 3 X 10(6) U IM three times a week for an additional 18 months in a single institution study. All treatment was stopped after 24 months. Sixty-nine percent of patients achieved a partial response, 11% a minor response, and 3% (one patient) had stable disease. Six patients (17%) did not respond to rIFN-alpha 2a. Two patients (6%) achieved a response but later progressed on treatment. A total of 23 patients completed 2 years of treatment and are evaluable for long-term follow-up at a median of 20 months postcompletion of therapy (range 9 to 32 months). Eleven patients (48%) have had progression of their disease at a median of 10 months (range .5 to 25 months) after treatment was discontinued. Statistical analysis of pretreatment patient characteristics did not reveal any factor(s) associated with a high probability of responding to rIFN-alpha 2a; however, analysis of post-treatment variables measured after 2 years of treatment suggested that a low platelet count was associated with a high rate of disease progression. These findings are compared with other published trials using rIFN-alpha 2b, a similar but not identical rIFN preparation. We conclude that while rIFN-alpha 2a has a high overall response incidence, the rate of disease progression after therapy is discontinued approaches 50%, and that a subset of patients can be identified who are at high risk for recurrence after completing 2 years of treatment.

Sign in / Sign up

Export Citation Format

Share Document